Mirum Pharmaceuticals posts strong Q3 sales, raises full‑year guidance and secures FDA approval for ATEBRIOZ
Mirum Pharmaceuticals reported third‑quarter 2026 net product sales of $185.7 million, a 40% year‑over‑year increase driven by LIVMARLI and bile‑acid medicines. The company received U.S. FDA approval and launched ATEBRIOZ for fibrodysplasia ossificans progressiva and announced positive Phase 3 results for LIVMARLI, ATEBRIOZ and brelovitug. It lifted its full‑year net product‑sales outlook to $715 million‑$720 million and plans several regulatory submissions in 2027.
Why it matters
The higher guidance raises revenue expectations for the next twelve months, which could improve cash flow forecasts and reduce the need for additional financing. The FDA approval adds a new marketed product, expanding Mirum’s revenue base.
Key facts
- 1Q3 2026 net product sales were $185.7 million. stocktitan.net
- 2LIVMARLI generated $133.4 million in net product sales, up 45% versus Q3 2025. sec.gov
- 3Bile‑acid medicines contributed $52.3 million, up 28% versus Q3 2025. sec.gov
- 4Full‑year net product‑sales guidance was increased to a range of $715 million to $720 million. sec.gov
- 5U.S. FDA approved and launched ATEBRIOZ for fibrodysplasia ossificans progressiva. sec.gov
- 6Positive Phase 3 readouts were announced for LIVMARLI, ATEBRIOZ and brelovitug. stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.